Rapid, Reliable and Ready
The first and only indicated therapy for Acquired Fibrinogen Deficiency (AFD) in Canada
fibryga (Fibrinogen Concentrate [Human], 1 g/vial) is a sterile, freeze-dried preparation of highly purified fibrinogen. It is indicated for the treatment of acute bleeding episodes and perioperative prophylaxis in adult and pediatric patients with congenital afibrinogenemia and hypofibrinogenemia.
Why fibryga?
Ready in Minutes
Reconstitutes in ~5 minutes to support rapid hemostasis in emergency and perioperative settings.1
Accurate Dose Every Time
Each vial delivers 1 g of Fibrinogen Concentrate.1
Shelf-Stable at room temperature
No refrigeration needed for storage or use making it available at point of care.1
fibryga is ready when required
fibryga is reconstituted in under 5 minutes and is suited for rapid preparation at the bedside, in the blood bank, or medical emergency transport services.
Now with Nextaro
Nextaro is an environmentally sustainable, purpose-built reconstitution device that provides a simpler, safer, and user-friendly experience, ensuring greater efficiency in reconstitution.
Discover how Nextaro simplifies reconstitution with fewer steps, double filtration, and intuitive handling that minimizes training requirements. Learn more.
Our medical affairs and hospital specialist teams are
happy to support you with an in-service session, demo kits, and training materials.
Why leading hospital teams in Canada use fibryga?
| Fibryga | Riastap | Cryoprecipitate | |
|---|---|---|---|
| Pathogen Reduction | Double virus inactivation | Single virus inactivation | Non-purified component that contains other clotting factors4 |
| Can be stored at room temperature | Yes1 | No2 Refrigeration is required. |
No. Refrigeration is required. |
| Reconstituted under 5 minutes | Yes1 | No2 | No2 |
| Preparation | Readily available FORMA-05 showed that compared to cryoprecipitate, Fibryga was delivered to the OR ~45 Minutes earlier and was administered ~24 minutes earlier 3 | Warm to room temperature before administration2 | Requires thawing4 |
| Stability after reconstitution | 24 hours at room temperature1 | 8 hours at room temperature2 | 4 hours4 |
| Clinical data in AFD | FIBRES, FORMA-05 | Not indicated for AFD2 | FORMA-05 showed Fibryga was non-inferior to Cryoprecipitate for hemostatic efficacy and safety in AFD3 |
Switching to fibryga
Switching to fibryga is easy and doesn’t require extensive training.
For any support regarding adding fibryga to your hospital’s formulary or conducting a budget impact analysis, please get in touch with our product and medical affairs teams.
Indications and important safety information for Fibryga
Indications
Fibryga (Fibrinogen concentrate (human)) is indicated for the treatment of acute bleeding episodes and perioperative prophylaxis in adult and pediatric patients with congenital afibrinogenemia and hypofibrinogenemia. FIBRYGA® may be used as a complementary therapy during the management of uncontrolled severe bleeding in patients with acquired fibrinogen deficiency in the course of surgical interventions.
- Pediatrics (12-17 years of age): Clinical studies of FIBRYGA® included 13 pediatric patients 12 to 17 years with congenital afibrinogenemia. Health Canada has authorized an indication for pediatric use in this age range.
- Pediatrics (<12 years of age): Clinical studies of FIBRYGA® included 14 pediatric patients <12 years of age years with congenital afibrinogenemia. Health Canada has authorized an indication for pediatric use in this age range
- Geriatrics (> 65 years of age): Clinical studies of FIBRYGA® did not include patients > 65 years of age with congenital afibrinogenemia or hypofibrinogenemia to determine whether they respond differently from younger patients.
Contradictions
Fibryga is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Please see the product monograph for full prescribing information. This information is only intended for healthcare professionals practicing in Canada.
References
1: Product Monograph fibryga, October 2024.
https://www.octapharma.ca/api/download/x/cb340082a5/fibryga_en_oct-24-2024.pdf
2: Product Monograph Riastap, May 2020.
http://labeling.cslbehring.ca/PM/CA/RiaSTAP/EN/RiaSTAP-Product-Monograph.pdf
3: FORMA-05
Efficacy of fibrinogen concentrate in major abdominal surgery – A prospective, randomized, controlled study in cytoreductive surgery for pseudomyxoma peritonei:
https://www.sciencedirect.com/science/article/pii/S1538783622015021
4. Blood Components, 2025 by Canadian Blood Services. Authored by: Lianne Rotin, MD, PhD, FRCPC, Johnathan Mack, MD, FRCPC.
https://professionaleducation.blood.ca/en/transfusion/clinical-guide/blood-components#17